How much is a Nuro stock worth?
One share of NURO stock can currently be purchased for approximately $4.25. How much money does NeuroMetrix make? NeuroMetrix has a market capitalization of $28.37 million and generates $8.25 million in revenue each year. The medical device company earns $-2.28 million in net income (profit) each year or ($0.42) on an earnings per share basis.
Who buys NeuroMetrix (Nuro)?
NURO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Advisor Group Holdings Inc., and State Street Corp. Company insiders that have bought NeuroMetrix stock in the last two years include Shai Gozani, and Topline Capital Management, Ll.
Will NeuroMetrix (Nuro) outperform the S&P 500 over the long term?
NeuroMetrix has received 71.72% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about NeuroMetrix and other stocks. Vote “Outperform” if you believe NURO will outperform the S&P 500 over the long term.
What is NeuroMetrix's stock symbol?
What is NeuroMetrix's stock symbol? NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO." Who are NeuroMetrix's major shareholders?
Is Nuro stock a good buy?
Is Neurometrix Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: NURO) stock is to Strong Buy NURO stock.
What is the future for Nuro stock?
NeuroMetrix Inc (NASDAQ:NURO) The 1 analysts offering 12-month price forecasts for NeuroMetrix Inc have a median target of 50.00, with a high estimate of 50.00 and a low estimate of 50.00. The median estimate represents a +1,240.48% increase from the last price of 3.73.
Is Nuro shorted?
Short Shares Availability This table shows the number of shares of US:NURO available to be shorted at a leading prime brokerage.
Why did Nuro stock go up today?
NeuroMetrix (NASDAQ:NURO) stock is rocketing higher on Tuesday thanks to the U.S. Food and Drug Administration (FDA) granting it Breakthrough Designation for one of its devices.
How many shares does Nuro have?
Share StatisticsAvg Vol (3 month) 31.69MShares Outstanding 57.13MImplied Shares Outstanding 6N/AFloat 86.46M% Held by Insiders 11.42%7 more rows
Who owns Nuro?
Nuro is an American robotics company based in Mountain View, California and founded by Jiajun Zhu and Dave Ferguson.
What is the short interest on Nuro?
(6.27%). Which stocks are the most shorted right now?
Why is NeuroMetrix stock dropping?
NeuroMetrix Inc. shares on Friday fell 17% to $4.58, a day after the company said the Food and Drug Administration gave De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.
Can I buy Neuralink stock?
There is no minimum order limit. You can invest in the tokenized shares of Neuralink or any other company listed on the exchange with as little as $1. And the company will convert your funds to parts of a whole share.
What kind of company is NeuroMetrix?
healthcare companyNeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico.
Why is NeuroMetrix stock dropping?
NeuroMetrix Inc. shares on Friday fell 17% to $4.58, a day after the company said the Food and Drug Administration gave De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.
What is the stock symbol for Nuro robotics?
Stock Quote (U.S.: Nasdaq) | MarketWatch....$ 3.4500.CloseChgChg %$3.30000.01000.30%
Is Nuro a real vehicle?
Nuro is one of the few US companies to be operating fully driverless vehicles — that is, vehicles without safety drivers behind the wheel — on public roads today. Its R2 vehicle is about half as wide as a compact sedan, shorter than most cars, and there's no room inside for human passengers or drivers.
What kind of company is NeuroMetrix?
healthcare companyNeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico.
How has NeuroMetrix's stock price performed in 2022?
NeuroMetrix's stock was trading at $5.02 at the beginning of the year. Since then, NURO shares have decreased by 29.0% and is now trading at $3.565...
Are investors shorting NeuroMetrix?
NeuroMetrix saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 429,100 shares, an increase of...
When is NeuroMetrix's next earnings date?
NeuroMetrix is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022. View our earnings forecast for NeuroMetr...
How were NeuroMetrix's earnings last quarter?
NeuroMetrix, Inc. (NASDAQ:NURO) announced its quarterly earnings results on Tuesday, April, 26th. The medical device company reported ($0.14) EPS f...
When did NeuroMetrix's stock split? How did NeuroMetrix's stock split work?
NeuroMetrix's stock reverse split on the morning of Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The numb...
Who are NeuroMetrix's key executives?
NeuroMetrix's management team includes the following people: Dr. Shai N. Gozani M.D. , Ph.D., Founder, Chairman, CEO, Pres & Sec. (Age 57, Pay $...
What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?
10 employees have rated NeuroMetrix CEO Shai N. Gozani on Glassdoor.com . Shai N. Gozani has an approval rating of 57% among NeuroMetrix's employe...
Who are some of NeuroMetrix's key competitors?
Some companies that are related to NeuroMetrix include Asensus Surgical (ASXC) , Neuronetics (STIM) , Cytosorbents (CTSO) , Repro Med Systems (...
What other stocks do shareholders of NeuroMetrix own?
Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (M...
How much is NeuroMetrix's net loss in 2021?
When is NeuroMetrix earnings call 2021?
The Q1 2021 net loss of $60 thousand, or $0.02 per share, compares favorably with the net loss of $657 thousand, or $0.45 per share, in Q1 2020. Company to Host Live Conference Call and Webcast NeuroMetrix will host a conference call at 8:00 a.m. Eastern today, April 22, 2021.
What is NeuroMetrix 2021?
NEW YORK, NY / ACCESSWIRE / April 22, 2021 / NeuroMetrix, Inc. (NASDAQ:NURO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 22, 2021 at 8:00 AM Eastern Time.
When will NeuroMetrix release its results?
(Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: Revenue of $2.1 million was up slightly from Q3 2020. Gross margin on revenue was $1.4 million, a 70.0% gross margin rate. This was a decrease of 3.6 percentage points from $1.5 m
Is NeuroMetrix a high volume stock?
(Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on April 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on April 22, 2021 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 9554608. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab. A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 9554608. The replay will be available for one week after the conference call. About NeuroMetrix NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter. For more information, visit www.NeuroMetrix.com. NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief Financial [email protected] Source: NeuroMetrix, Inc.
What is the ticker symbol for NeuroMetrix?
NeuroMetrix Inc (NASDAQ: NURO) shares are surging higher Friday on abnormally high volume amid an increase in retail investor interest around the low-float stock. The average session volume is just under 8 million. The trading volume for Friday's session was nearing 50 million at publication time. NeuroMetrix is trending across social media platforms. It was among the top three trending stocks on Stocktwits at publication time. NeuroMetrix is a commercial stage healthcare company that produces b
What is the P/E ratio of NeuroMetrix?
NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."
What is a neurometrix?
The P/E ratio of NeuroMetrix is -23.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
When did NeuroMetrix reverse split?
NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables. It offers an over-the-counter wearable therapeutic device for chronic pain, the Quell Health Cloud, DPNCheck, and pain management devices to treat chronic pain, nerve diseases, and sleep disorder. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.
Is there enough data for NeuroMetrix?
Shares of NeuroMetrix reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of NeuroMetrix stock prior to the reverse split would have 13 shares after the split.
Does NeuroMetrix pay dividends?
There is not enough analysis data for NeuroMetrix.
Component Grades
NeuroMetrix does not currently pay a dividend.
NURO Broker Recommendations Summary
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now. Just click the link above.
Stock Price Forecast
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
Analyst Recommendations
The 1 analysts offering 12-month price forecasts for NeuroMetrix Inc have a median target of 50.00, with a high estimate of 50.00 and a low estimate of 50.00. The median estimate represents a +972.96% increase from the last price of 4.66.
How much is NeuroMetrix stock worth in 2021?
The current consensus among 1 polled investment analysts is to Buy stock in NeuroMetrix Inc. This rating has held steady since October, when it was upgraded from a Hold rating. Move your mouse over past months for detail
What does it mean when the stock is $3.17?
The NeuroMetrix stock price gained 1.48% on the last trading day (Friday, 9th Jul 2021), rising from $3.37 to $3.42. During the day the stock fluctuated 3.64% from a day low at $3.30 to a day high of $3.42. The price has fallen in 5 of the last 10 days and is down by -7.57% for this period. Volume fell on the last day by -790 shares and in total, 39 thousand shares were bought and sold for approximately $133.33 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Is NeuroMetrix stock A Buy?
The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $3.17 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift.
NURO earnings per share forecast
NeuroMetrix holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
NeuroMetrix Stock Forecast FAQ
What is NURO 's earnings per share in the next 1 years based on estimates from 1 analysts?